Prepubertal gynecomastia during growth hormone therapy.
We report 22 cases of prepubertal gynecomastia diagnosed during growth hormone (GH) treatment. The age and dose range were 2 to 12 years and 0.18 [corrected] to 0.3 mg/kg per week, respectively. In most of the patients, gynecomastia appeared between 0.5 and 7 months after GH was started. Three boys were using drugs other than GH. This condition appears to be self-limited and benign.
Malozowski
S
S
Division of Metabolism and Endocrine Drug Products, U.S. Food and Drug Administration, Rockville, Maryland 20857, USA.
Stadel
B V
BV
D002648:Child; D002675:Child, Preschool; D013006:Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006177:Gynecomastia / Q000139:chemically induced*; D006801:Humans; D008297:Male
D013006:Growth Hormone